MCID: LYM048
MIFTS: 30

Lymphoma, Large-Cell, Immunoblastic

Categories: Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoma, Large-Cell, Immunoblastic

MalaCards integrated aliases for Lymphoma, Large-Cell, Immunoblastic:

Name: Lymphoma, Large-Cell, Immunoblastic 19 75 36
Large Cell Immunoblastic Lymphoma 19
Lymphoma Large Cell Immunoblastic 53
Immunoblastic Large-Cell Lymphoma 71

Classifications:



External Ids:

UMLS 71 C0079746

Summaries for Lymphoma, Large-Cell, Immunoblastic

GARD: 19 A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.

MalaCards based summary: Lymphoma, Large-Cell, Immunoblastic, also known as large cell immunoblastic lymphoma, is related to burkitt lymphoma and peripheral t-cell lymphoma. An important gene associated with Lymphoma, Large-Cell, Immunoblastic is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Overview of interferons-mediated signaling pathway and Immune response IL-23 signaling pathway. The drugs Iodine and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and liver.

Wikipedia: 75 Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Related Diseases for Lymphoma, Large-Cell, Immunoblastic

Diseases related to Lymphoma, Large-Cell, Immunoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 burkitt lymphoma 29.9 TIMP1 MYC
2 peripheral t-cell lymphoma 11.3
3 lymphoma 10.2
4 reticulosarcoma 10.2
5 lymphoma, hodgkin, classic 10.1
6 immune deficiency disease 10.1
7 anaplastic large cell lymphoma 10.1
8 richter's syndrome 10.1
9 polyclonal hypergammaglobulinemia 10.1
10 acquired immunodeficiency syndrome 10.1
11 laryngeal squamous cell carcinoma 9.7 TIMP1 MYC
12 fibrosarcoma 9.7 TIMP1 MYC
13 colon adenocarcinoma 9.7 TIMP1 MYC
14 arthritis 9.7 TIMP1 MYC
15 eye disease 9.6 TIMP1 MYC
16 connective tissue disease 9.6 TIMP1 MYC
17 dilated cardiomyopathy 9.5 TIMP1 MYC

Graphical network of the top 20 diseases related to Lymphoma, Large-Cell, Immunoblastic:



Diseases related to Lymphoma, Large-Cell, Immunoblastic

Symptoms & Phenotypes for Lymphoma, Large-Cell, Immunoblastic

Drugs & Therapeutics for Lymphoma, Large-Cell, Immunoblastic

Drugs for Lymphoma, Large-Cell, Immunoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Aldesleukin Approved Phase 3 110942-02-4
3
Cadexomer iodine Experimental Phase 3 94820-09-4
4 Tositumomab I-131 Phase 3
5 Analgesics Phase 3
6 Interleukin-2 Phase 3
7 Analgesics, Non-Narcotic Phase 3
8
Melphalan Approved Phase 2 148-82-3 4053 460612
9
Etoposide Approved Phase 2 33419-42-0 36462
10
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
11
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
12
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
13
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
14
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
17
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
18
Mitoxantrone Approved, Investigational Phase 2 70476-82-3, 65271-80-9 4212
19
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
20
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
21
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
22
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
23
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
25
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
26
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
27
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
28
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
29
Rasburicase Approved, Investigational Phase 2 134774-45-1
30
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
31
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
32
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
33
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
34
Daratumumab Approved Phase 2 945721-28-8
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
37
Nivolumab Approved Phase 2 946414-94-4
38
Picropodophyllin Approved, Investigational Phase 1, Phase 2 518-28-5, 477-47-4 10607 72435
39
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
40
Hydrocortisone succinate Approved Phase 1, Phase 2 2203-97-6 3643
41
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
42
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 3640 5754
43
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2 25183872
44
Busulfan Approved, Investigational Phase 2 55-98-1 2478
45
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
46
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
47
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
48
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
49
Ifosfamide Approved Phase 2 3778-73-2 3690
50
Iron Approved Phase 2 7439-89-6 29936

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
2 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
3 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
4 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
5 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
6 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
7 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
8 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
9 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
10 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
11 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
12 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
13 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
14 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
15 Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas Completed NCT00002003 Phase 2 Mitoxantrone hydrochloride;Etoposide
16 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
17 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
18 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
19 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
20 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
21 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
22 A Phase II Study of CCI-779 in B-cell Lymphoma and CLL Completed NCT00290472 Phase 2 temsirolimus
23 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
24 A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies Completed NCT00005811 Phase 2 topotecan hydrochloride
25 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
27 A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy Completed NCT00057811 Phase 2 doxorubicin hydrochloride;cyclophosphamide;methotrexate;rasburicase;leucovorin calcium;prednisone;methylprednisolone;cytarabine;etoposide;vincristine sulfate;hydrocortisone sodium succinate
28 A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma Completed NCT00049036 Phase 2 etoposide;doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide
29 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
30 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
31 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
32 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
33 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
34 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Completed NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;procarbazine hydrochloride
35 A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma Completed NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
36 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
37 A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT01475058 Phase 1, Phase 2
38 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
39 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
40 A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma Recruiting NCT04676360 Phase 2 Belantamab Mafodotin
41 A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells Recruiting NCT02797470 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan
42 An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial) Recruiting NCT04915248 Phase 2 Daratumumab;Bortezomib;Dexamethasone
43 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting NCT03038672 Phase 2 Varlilumab
45 A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen Active, not recruiting NCT02481310 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride;Etoposide;Ixazomib Citrate;Methotrexate;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
46 Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma Active, not recruiting NCT01092182 Phase 2 EPOCH-R;EPOCH-RR
47 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Active, not recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
48 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
49 A Phase II Study of Rituximab (IND #7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia Terminated NCT00058461 Phase 2 ifosfamide;etoposide;carboplatin;methotrexate;cytarabine
50 RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) Terminated NCT01044745 Phase 2 rituximab;mycophenolate mofetil;tacrolimus;anti-thymocyte globulin;cyclophosphamide;fludarabine phosphate;busulfan

Search NIH Clinical Center for Lymphoma, Large-Cell, Immunoblastic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Large-Cell, Immunoblastic cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Large-Cell, Immunoblastic

Anatomical Context for Lymphoma, Large-Cell, Immunoblastic

Organs/tissues related to Lymphoma, Large-Cell, Immunoblastic:

MalaCards : Bone Marrow, T Cells, Liver, Bone, Myeloid, Lung, Spleen

Publications for Lymphoma, Large-Cell, Immunoblastic

Articles related to Lymphoma, Large-Cell, Immunoblastic:

(show all 43)
# Title Authors PMID Year
1
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. 53 62
8695812 1996
2
Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. 53 62
1421616 1992
3
Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid. 62
17488258 2007
4
Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. 62
17416237 2007
5
Hepatosplenic large cell immunoblastic lymphoma in a bottlenose dolphin (Tursiops truncatus) with high levels of polychlorinated biphenyl congeners. 62
15737353 2005
6
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. 62
15564497 2004
7
A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. 62
10752986 2000
8
Primary malignant lymphoma of the duodenum: report of a case. 62
9951887 1998
9
Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. 62
9446632 1998
10
Secondary pleural involvement by an AIDS-related anaplastic large cell (CD30+) lymphoma simulating metastatic adenocarcinoma. 62
9484639 1998
11
Anaplastic large-cell lymphoma (Ki-1 lymphoma) and diffuse large-cell immunoblastic lymphoma: two diagnostic problem cases. 62
9491216 1998
12
Optimal primer selection for clonality assessment by polymerase chain reaction analysis. III. Intermediate and high-grade B-cell neoplasms. 62
8617481 1996
13
Epstein-Bar virus and progression of non-Hodgkin's lymphoma to Ki-1-positive, anaplastic large cell phenotype. 62
7675777 1995
14
B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter's syndrome. 62
7872259 1995
15
Combined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: a phase II study of CHOP/bleomycin/methotrexate alternating with ifosfamide/methotrexate/etoposide. 62
7542471 1995
16
Human herpesvirus-6-associated malignant lymphoma in a bone marrow transplant recipient. 62
15566776 1994
17
Detection and characterization of Epstein-Barr virus in clinical specimens. 62
8053485 1994
18
Endobronchial HIV associated lymphoma. 62
8016780 1994
19
Lung carcinoma mimicking malignant lymphoma: report of three cases. 62
8291450 1993
20
Epstein-Barr virus and primary lung lymphoma: a study utilizing the polymerase chain reaction. 62
8248115 1993
21
Incidence of Epstein-Barr virus in AIDS-related lymphoma specimens. 62
8391077 1993
22
B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. 62
8391875 1993
23
Malignant lymphomas involving the ovary. A clinicopathologic analysis of 39 cases. 62
8422111 1993
24
Biologic aspects of human immunodeficiency virus-related lymphoma. 62
1457505 1992
25
[Primary brain lymphoma]. 62
1748343 1991
26
AIDS-associated polyclonal lymphoma: identification of a new HIV-associated disease process. 62
1848889 1991
27
Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. 62
2265114 1990
28
Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. 62
2591946 1989
29
[Metastatic malignant lymphoma of the skull with extradural and extracranial extension. Case report]. 62
2479873 1989
30
Human immunodeficiency virus-associated large-cell immunoblastic lymphoma presenting as a perianal abscess. 62
2712677 1989
31
Primary adrenal lymphoma. 62
2644013 1989
32
Relapsing large cell immunoblastic lymphoma complicating well-differentiated lymphocytic lymphoma: a report of two cases showing prolonged survival with therapy. 62
3284695 1988
33
The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease) 62
3037883 1987
34
Malignant lymphoma, large cell immunoblastic clear cell showing unusual histologic picture. 62
2956826 1987
35
Bone marrow manifestations of peripheral T-cell lymphoma. A study of 30 cases. 62
3490173 1986
36
Recurrent chromosome abnormalities in adult T-cell lymphomas of peripheral T-cell origin. 62
3485582 1986
37
A case report of malignant lymphoma with Hashimoto's thyroiditis. 62
3838853 1985
38
Case report 269. Diagnosis: malignant lymphoma (large cell, immunoblastic type) with widespread dissemination in the skeleton as well as lymph nodes and probably the liver and spleen. 62
6547004 1984
39
Primary lymphoma of the brain associated with AIDS. A study of one case. 62
6548075 1984
40
Terminal deoxynucleotidyl transferase in non-Hodgkin's lymphoma. 62
6356870 1983
41
Expression of a T-cell antigen (Leu-1) by B-cell lymphomas. 62
6605688 1983
42
Malignant lymphoma, diffuse mixed small and large cell. A clinicopathologic study of 47 cases. 62
6687699 1983
43
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. 62
7133054 1982

Variations for Lymphoma, Large-Cell, Immunoblastic

Expression for Lymphoma, Large-Cell, Immunoblastic

Search GEO for disease gene expression data for Lymphoma, Large-Cell, Immunoblastic.

Pathways for Lymphoma, Large-Cell, Immunoblastic

Pathways related to Lymphoma, Large-Cell, Immunoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.87 TIMP1 MYC
2
Show member pathways
11.85 TIMP1 MYC
3 11.29 TIMP1 MYC
4 10.99 TIMP1 MYC
5 10.61 TIMP1 MYC
6 9.74 TIMP1 MYC

GO Terms for Lymphoma, Large-Cell, Immunoblastic

Sources for Lymphoma, Large-Cell, Immunoblastic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....